DE69807679D1 - Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren - Google Patents

Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren

Info

Publication number
DE69807679D1
DE69807679D1 DE69807679T DE69807679T DE69807679D1 DE 69807679 D1 DE69807679 D1 DE 69807679D1 DE 69807679 T DE69807679 T DE 69807679T DE 69807679 T DE69807679 T DE 69807679T DE 69807679 D1 DE69807679 D1 DE 69807679D1
Authority
DE
Germany
Prior art keywords
human
immunoglobulines
conjugates
proteins
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69807679T
Other languages
English (en)
Other versions
DE69807679T2 (de
Inventor
N Brems
L French
A Speed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/059,467 external-priority patent/US20020019352A1/en
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DE69807679D1 publication Critical patent/DE69807679D1/de
Publication of DE69807679T2 publication Critical patent/DE69807679T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE69807679T 1997-04-17 1998-04-16 Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren Expired - Lifetime DE69807679T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84397197A 1997-04-17 1997-04-17
US09/059,467 US20020019352A1 (en) 1997-04-17 1998-04-14 Stable, active, human ob protein compositions and methods
PCT/US1998/007828 WO1998046257A1 (en) 1997-04-17 1998-04-16 Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods

Publications (2)

Publication Number Publication Date
DE69807679D1 true DE69807679D1 (de) 2002-10-10
DE69807679T2 DE69807679T2 (de) 2003-07-31

Family

ID=26738785

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69807679T Expired - Lifetime DE69807679T2 (de) 1997-04-17 1998-04-16 Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren

Country Status (12)

Country Link
EP (1) EP0977583B1 (de)
JP (1) JP4086908B2 (de)
CN (1) CN1202862C (de)
AT (1) ATE223229T1 (de)
AU (1) AU7132798A (de)
CA (1) CA2286098C (de)
DE (1) DE69807679T2 (de)
ES (1) ES2183351T3 (de)
HK (1) HK1023513A1 (de)
HU (1) HU226175B1 (de)
IL (1) IL132380A0 (de)
WO (1) WO1998046257A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
WO1997018833A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CN1810832B (zh) 1998-10-23 2012-12-12 麒麟-安姆根有限公司 与MPl受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽
AU1134000A (en) * 1998-10-27 2000-05-15 Eli Lilly And Company Prevention of muscle mass loss with leptin receptor ligands
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
CA2407956A1 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides as therapeutic agents
JP2004525621A (ja) * 2001-01-18 2004-08-26 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング グルコセレブロシダーゼ活性を有する二機能性融合タンパク質
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7026326B2 (en) 2002-05-21 2006-04-11 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1702069A2 (de) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Auf onkofötales fibronectin gerichtetes interleukin-12
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
KR102469853B1 (ko) 2008-04-11 2022-11-22 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
CA2725143A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
EP2352510A4 (de) 2008-11-04 2012-08-29 Neurotez Inc Leptinzusammensetzungen und verfahren zur behandlung von progressiven kognitiven störungen infolge der ansammlung von neurofibrillären bündeln und amyloid-beta
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
AU2011337704B2 (en) * 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
AU2013323528B2 (en) 2012-09-27 2016-11-10 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
DK3074033T3 (en) 2013-11-26 2019-02-11 Childrens Medical Ct Corp RELATIONSHIPS FOR TREATING ADIPOSITAS AND PROCEDURES FOR USING THEREOF
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
PE20221834A1 (es) 2014-12-19 2022-11-29 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina
RU2746356C2 (ru) 2014-12-19 2021-04-12 Чугаи Сейяку Кабусики Кайся Антитела к с5 и способы их применения
KR20170110129A (ko) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
SI3509624T1 (sl) 2016-09-12 2023-12-29 Amryt Pharmaceuticals, Inc., Postopki detektiranja nevtralizirajočih protiteles proti leptinu
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559208A (en) * 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
ATE267255T1 (de) * 1995-12-27 2004-06-15 Genentech Inc Ob proteinderivate mit verlängerter halbwertzeit
CA2275183A1 (en) * 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods

Also Published As

Publication number Publication date
DE69807679T2 (de) 2003-07-31
HK1023513A1 (en) 2000-09-15
EP0977583A1 (de) 2000-02-09
CA2286098C (en) 2009-07-07
CA2286098A1 (en) 1998-10-22
IL132380A0 (en) 2001-03-19
ES2183351T3 (es) 2003-03-16
ATE223229T1 (de) 2002-09-15
CN1202862C (zh) 2005-05-25
HUP0002831A3 (en) 2005-11-28
EP0977583B1 (de) 2002-09-04
JP2002512612A (ja) 2002-04-23
WO1998046257A1 (en) 1998-10-22
AU7132798A (en) 1998-11-11
CN1274289A (zh) 2000-11-22
WO1998046257A8 (en) 2000-01-27
HU226175B1 (en) 2008-06-30
JP4086908B2 (ja) 2008-05-14
HUP0002831A2 (hu) 2000-12-28

Similar Documents

Publication Publication Date Title
DE69807679D1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
ES2196031T3 (es) Derivados peptidicos terapeutico.
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
DE69330643T2 (de) Monoklonaler antikörper, welcher spezifisch an vaskularisiertes tumorendothelium bindet und verwendungen davon
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
DE69637781D1 (de) Für den il-13 rezeptor spezifische chimäre proteine und ihre verwendungen
DK0754229T3 (da) Afamin: et humant serum albumin-lignende protein
ATE260977T1 (de) Immunoglobulin-bindende proteine
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
DE59509948D1 (de) Konjugat aus einem wirkstoff und einem nicht als körperfremd angesehenen, nativen protein
ATE293996T1 (de) Lage-spezifische markierung von disulfide- enthaltenden zielgerichteten vektoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition